
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
        <meta name="description" content="Evidence-based clinical decision support templates for neurological diagnoses">
      
      
      
        <link rel="canonical" href="https://blondarb.github.io/neuro-plans/plans/autoimmune-encephalitis/">
      
      
        <link rel="prev" href="../hsv-encephalitis/">
      
      
        <link rel="next" href="../acute-myelopathy/">
      
      
        
      
      
      <link rel="icon" href="../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.7.1">
    
    
      
        <title>Autoimmune Encephalitis - Neuro Clinical Plans</title>
      
    
    
      <link rel="stylesheet" href="../../assets/stylesheets/main.484c7ddc.min.css">
      
        
        <link rel="stylesheet" href="../../assets/stylesheets/palette.ab4e12ef.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../../assets/css/custom.css">
    
    <script>__md_scope=new URL("../..",location),__md_hash=e=>[...e].reduce(((e,_)=>(e<<5)-e+_.charCodeAt(0)),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#autoimmune-encephalitis" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

  

<header class="md-header md-header--shadow" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../.." title="Neuro Clinical Plans" class="md-header__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3zm0 5h18v2H3zm0 5h18v2H3z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Neuro Clinical Plans
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Autoimmune Encephalitis
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a4 4 0 0 0-4 4 4 4 0 0 0 4 4 4 4 0 0 0 4-4 4 4 0 0 0-4-4m0 10a6 6 0 0 1-6-6 6 6 0 0 1 6-6 6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 18c-.89 0-1.74-.2-2.5-.55C11.56 16.5 13 14.42 13 12s-1.44-4.5-3.5-5.45C10.26 6.2 11.11 6 12 6a6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var palette=__md_get("__palette");if(palette&&palette.color){if("(prefers-color-scheme)"===palette.color.media){var media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']");palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent")}for(var[key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      
      
        <label class="md-header__button md-icon" for="__search">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        </label>
        <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"/></svg>
        </button>
      </nav>
      
        <div class="md-search__suggest" data-md-component="search-suggest"></div>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
      
    
    
      <div class="md-header__source">
        <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    



<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../.." title="Neuro Clinical Plans" class="md-nav__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    Neuro Clinical Plans
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../.." class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Home
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../../clinical/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Interactive Clinical Tool
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--active md-nav__item--section md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3" checked>
        
          
          <label class="md-nav__link" for="__nav_3" id="__nav_3_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    Clinical Plans
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_3_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Clinical Plans
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Overview
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_2" >
        
          
          <label class="md-nav__link" for="__nav_3_2" id="__nav_3_2_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Seizures & Epilepsy
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_2_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_2">
            <span class="md-nav__icon md-icon"></span>
            
  
    Seizures & Epilepsy
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../status-epilepticus/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Status Epilepticus
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../new-onset-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    New Onset Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../breakthrough-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Breakthrough Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_3" >
        
          
          <label class="md-nav__link" for="__nav_3_3" id="__nav_3_3_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Stroke & Vascular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Stroke & Vascular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../acute-ischemic-stroke/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Ischemic Stroke
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../transient-ischemic-attack/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Transient Ischemic Attack
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../intracerebral-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Intracerebral Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../subarachnoid-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Subarachnoid Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_4" >
        
          
          <label class="md-nav__link" for="__nav_3_4" id="__nav_3_4_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuromuscular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../guillain-barre-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Guillain-Barré Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../myasthenia-gravis-crisis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenic Crisis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../myasthenia-gravis-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenia Gravis - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../neuromuscular-respiratory-failure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular Respiratory Failure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../peripheral-neuropathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Peripheral Neuropathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
    
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--active md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3_5" checked>
        
          
          <label class="md-nav__link" for="__nav_3_5" id="__nav_3_5_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    CNS Infections
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_5_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_3_5">
            <span class="md-nav__icon md-icon"></span>
            
  
    CNS Infections
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../bacterial-meningitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bacterial Meningitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../hsv-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    HSV Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
        
      
      
        <label class="md-nav__link md-nav__link--active" for="__toc">
          
  
  
  <span class="md-ellipsis">
    
  
    Autoimmune Encephalitis
  

    
  </span>
  
  

          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  
  <span class="md-ellipsis">
    
  
    Autoimmune Encephalitis
  

    
  </span>
  
  

      </a>
      
        

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#clinical-decision-support-notes" class="md-nav__link">
    <span class="md-ellipsis">
      
        CLINICAL DECISION SUPPORT NOTES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#change-log" class="md-nav__link">
    <span class="md-ellipsis">
      
        CHANGE LOG
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_6" >
        
          
          <label class="md-nav__link" for="__nav_3_6" id="__nav_3_6_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Spinal Emergencies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_6_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_6">
            <span class="md-nav__icon md-icon"></span>
            
  
    Spinal Emergencies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../acute-myelopathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Myelopathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../spinal-cord-compression-malignant/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Spinal Cord Compression (Malignant)
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../cauda-equina-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Cauda Equina Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../epidural-abscess/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Epidural Abscess
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_7" >
        
          
          <label class="md-nav__link" for="__nav_3_7" id="__nav_3_7_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuro-Oncology
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_7_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_7">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuro-Oncology
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../brain-metastases/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Brain Metastases
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_8" >
        
          
          <label class="md-nav__link" for="__nav_3_8" id="__nav_3_8_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Critical Care
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_8_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_8">
            <span class="md-nav__icon md-icon"></span>
            
  
    Critical Care
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../elevated-icp-management/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Elevated ICP Management
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_9" >
        
          
          <label class="md-nav__link" for="__nav_3_9" id="__nav_3_9_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Demyelinating
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_9_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_9">
            <span class="md-nav__icon md-icon"></span>
            
  
    Demyelinating
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../ms-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    MS New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_10" >
        
          
          <label class="md-nav__link" for="__nav_3_10" id="__nav_3_10_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Headache
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_10_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_10">
            <span class="md-nav__icon md-icon"></span>
            
  
    Headache
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../migraine/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Migraine
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_11" >
        
          
          <label class="md-nav__link" for="__nav_3_11" id="__nav_3_11_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Movement Disorders
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_11_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_11">
            <span class="md-nav__icon md-icon"></span>
            
  
    Movement Disorders
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../parkinsons-disease-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Parkinson's Disease - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../essential-tremor/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Essential Tremor
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_12" >
        
          
          <label class="md-nav__link" for="__nav_3_12" id="__nav_3_12_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Dementia & Cognitive
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_12_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_12">
            <span class="md-nav__icon md-icon"></span>
            
  
    Dementia & Cognitive
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../dementia-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Dementia Evaluation
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../rapidly-progressive-dementia/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Rapidly Progressive Dementia
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_13" >
        
          
          <label class="md-nav__link" for="__nav_3_13" id="__nav_3_13_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Cranial Neuropathies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_13_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_13">
            <span class="md-nav__icon md-icon"></span>
            
  
    Cranial Neuropathies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../bells-palsy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bell's Palsy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_14" >
        
          
          <label class="md-nav__link" for="__nav_3_14" id="__nav_3_14_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Other
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_14_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_14">
            <span class="md-nav__icon md-icon"></span>
            
  
    Other
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../vertigo-dizziness-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Vertigo / Dizziness
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--section md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_4" >
        
          
          <label class="md-nav__link" for="__nav_4" id="__nav_4_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    References
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    References
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/lp-reference/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    LP Reference
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/tracker/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Template Tracker
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#clinical-decision-support-notes" class="md-nav__link">
    <span class="md-ellipsis">
      
        CLINICAL DECISION SUPPORT NOTES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#change-log" class="md-nav__link">
    <span class="md-ellipsis">
      
        CHANGE LOG
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              
              <article class="md-content__inner md-typeset">
                
                  


  
  


<h1 id="autoimmune-encephalitis">Autoimmune Encephalitis<a class="headerlink" href="#autoimmune-encephalitis" title="Permanent link">&para;</a></h1>
<p><strong>VERSION:</strong> 1.0
<strong>CREATED:</strong> January 27, 2026
<strong>STATUS:</strong> Initial creation</p>
<hr />
<p><strong>DIAGNOSIS:</strong> Autoimmune Encephalitis</p>
<p><strong>ICD-10:</strong> G04.81 (Other autoimmune encephalitis)</p>
<p><strong>SYNONYMS:</strong> Autoimmune encephalitis, AE, anti-NMDA receptor encephalitis, anti-NMDAR encephalitis, limbic encephalitis, antibody-mediated encephalitis, paraneoplastic encephalitis, LGI1 encephalitis, CASPR2 encephalitis, rapid neurocognitive syndrome</p>
<p><strong>SCOPE:</strong> Diagnostic workup, acute treatment, and long-term management of suspected or confirmed autoimmune encephalitis. Covers antibody-mediated encephalitis (anti-NMDAR, LGI1, CASPR2, GABA-B, AMPA, DPPX, IgLON5, GABA-A, GAD65), first-line immunotherapy, second-line escalation, seizure management, psychiatric symptom management, ICU considerations, tumor screening, and long-term immunosuppression. For infectious encephalitis, use "HSV Encephalitis" template. For paraneoplastic syndromes without encephalitis, use "Paraneoplastic Syndrome" template. For status epilepticus management, use "Status Epilepticus" template.</p>
<hr />
<p><strong>PRIORITY KEY:</strong> STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>
<p>═══════════════════════════════════════════════════════════
SECTION A: ACTION ITEMS
═══════════════════════════════════════════════════════════</p>
<h2 id="1-laboratory-workup">1. LABORATORY WORKUP<a class="headerlink" href="#1-laboratory-workup" title="Permanent link">&para;</a></h2>
<h3 id="1a-essentialcore-labs">1A. Essential/Core Labs<a class="headerlink" href="#1a-essentialcore-labs" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC with differential</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Baseline; infection screen; pre-immunotherapy</td>
<td>Normal</td>
</tr>
<tr>
<td>CMP (BMP + LFTs)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Metabolic screen; renal/hepatic baseline for immunotherapy</td>
<td>Normal</td>
</tr>
<tr>
<td>TSH</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Thyroid encephalopathy mimic; Hashimoto encephalopathy screen</td>
<td>Normal</td>
</tr>
<tr>
<td>ESR</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Inflammatory/vasculitis screen</td>
<td>Normal (&lt;20 mm/hr)</td>
</tr>
<tr>
<td>CRP</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Inflammatory marker; infection screen</td>
<td>Normal</td>
</tr>
<tr>
<td>Urinalysis with culture</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>UTI as encephalopathy trigger</td>
<td>Negative</td>
</tr>
<tr>
<td>Blood cultures (x2 sets)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Rule out septic encephalopathy</td>
<td>No growth</td>
</tr>
<tr>
<td>Blood glucose</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Metabolic encephalopathy screen; pre-steroid baseline</td>
<td>Normal</td>
</tr>
<tr>
<td>HbA1c</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Glycemic status before high-dose steroids</td>
<td>&lt;5.7%</td>
</tr>
<tr>
<td>Ammonia</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Hepatic encephalopathy mimic</td>
<td>Normal</td>
</tr>
<tr>
<td>Lactate</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Sepsis screen; metabolic screen</td>
<td>Normal (&lt;2.0 mmol/L)</td>
</tr>
<tr>
<td>PT/INR, aPTT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Coagulopathy screen pre-LP; DIC screen</td>
<td>Normal</td>
</tr>
<tr>
<td>Magnesium</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Seizure threshold; metabolic screen</td>
<td>Normal</td>
</tr>
<tr>
<td>Phosphorus</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Metabolic screen</td>
<td>Normal</td>
</tr>
<tr>
<td>Procalcitonin</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td>Distinguish bacterial vs autoimmune etiology</td>
<td>Normal (&lt;0.1 ng/mL)</td>
</tr>
<tr>
<td>Troponin</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Cardiac involvement; autonomic instability assessment</td>
<td>Normal</td>
</tr>
<tr>
<td>CPK</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td>Rhabdomyolysis from prolonged seizures/catatonia</td>
<td>Normal</td>
</tr>
<tr>
<td>Urine drug screen</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Toxic/drug-induced encephalopathy mimic</td>
<td>Negative</td>
</tr>
<tr>
<td>Alcohol level</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Alcohol-related encephalopathy</td>
<td>Negative</td>
</tr>
<tr>
<td>Pregnancy test (females of childbearing age)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Eclampsia mimic; treatment planning (teratogenicity)</td>
<td>As applicable</td>
</tr>
<tr>
<td>Peripheral blood smear</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td>TTP/HUS screen if thrombocytopenia</td>
<td>Normal</td>
</tr>
<tr>
<td>LDH</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Hemolysis screen; tumor marker</td>
<td>Normal</td>
</tr>
<tr>
<td>Uric acid</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Tumor lysis risk if malignancy suspected</td>
<td>Normal</td>
</tr>
<tr>
<td>Lipase</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Pancreatitis-related encephalopathy</td>
<td>Normal</td>
</tr>
</tbody>
</table>
<h3 id="1b-autoimmune-antibody-panel">1B. Autoimmune Antibody Panel<a class="headerlink" href="#1b-autoimmune-antibody-panel" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-NMDAR antibody (serum AND CSF)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Most common autoimmune encephalitis; CSF more sensitive than serum; cell-based assay (CBA) preferred</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Anti-LGI1 antibody (serum AND CSF)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Limbic encephalitis; faciobrachial dystonic seizures (FBDS); hyponatremia</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Anti-CASPR2 antibody (serum AND CSF)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Limbic encephalitis; Morvan syndrome; neuromyotonia; neuropathic pain</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Anti-GABA-B antibody (serum AND CSF)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Limbic encephalitis with prominent seizures; 50% associated with SCLC</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Anti-AMPA antibody (serum AND CSF)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Limbic encephalitis; relapsing course; associated with thymoma, lung, breast</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Anti-DPPX antibody (serum AND CSF)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Encephalitis with hyperexcitability, GI symptoms, PERM</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Anti-IgLON5 antibody (serum AND CSF)</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Sleep disorder, bulbar dysfunction, gait instability, tau pathology</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Anti-GABA-A antibody (serum AND CSF)</strong></td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Refractory seizures/status epilepticus; often with thymoma</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Anti-GAD65 antibody (serum AND CSF)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Limbic encephalitis, stiff-person spectrum, cerebellar ataxia; high titers (&gt;20 nmol/L) significant</td>
<td>Negative or low titer</td>
</tr>
<tr>
<td><strong>Mayo Autoimmune Evaluation - Encephalopathy (serum)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Comprehensive panel: NMDAR, LGI1, CASPR2, GABA-B, AMPA, DPPX</td>
<td>All negative</td>
</tr>
<tr>
<td><strong>Mayo Autoimmune Evaluation - Encephalopathy (CSF)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>CSF panel: NMDAR, LGI1, CASPR2, GABA-B, AMPA, DPPX</td>
<td>All negative</td>
</tr>
<tr>
<td>ANA</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Lupus cerebritis screen</td>
<td>Negative or low titer</td>
</tr>
<tr>
<td>Anti-dsDNA</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If ANA positive; lupus evaluation</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-SSA/SSB (Ro/La)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Sjogren syndrome with CNS involvement</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-TPO antibodies</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Hashimoto encephalopathy (SREAT)</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-thyroglobulin antibodies</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Hashimoto encephalopathy (SREAT)</td>
<td>Negative</td>
</tr>
<tr>
<td>AQP4-IgG (NMO antibody)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>NMOSD overlap; cell-based assay preferred</td>
<td>Negative</td>
</tr>
<tr>
<td>MOG-IgG</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>MOGAD overlap; ADEM-like presentation</td>
<td>Negative</td>
</tr>
<tr>
<td>Complement C3, C4</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Lupus; complement-mediated disease</td>
<td>Normal</td>
</tr>
<tr>
<td>Quantitative immunoglobulins (IgG, IgA, IgM)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Baseline before immunotherapy; IgA deficiency (IVIG contraindication)</td>
<td>Normal</td>
</tr>
</tbody>
</table>
<p><em>Note: ALWAYS send BOTH serum AND CSF for antibody testing. CSF is more sensitive for anti-NMDAR; serum is more sensitive for anti-LGI1 and anti-CASPR2. Cell-based assay (CBA) is gold standard -- avoid ELISA-only testing. Mayo panels preferred for comprehensive evaluation. Results may take 1-3 weeks; do NOT wait for results before starting empiric immunotherapy if clinical suspicion is high.</em></p>
<h3 id="1c-rarespecialized-refractory-or-atypical">1C. Rare/Specialized (Refractory or Atypical)<a class="headerlink" href="#1c-rarespecialized-refractory-or-atypical" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-neuronal nuclear antibody type 1 (ANNA-1/anti-Hu)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Paraneoplastic; SCLC, neuroblastoma</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-neuronal nuclear antibody type 2 (ANNA-2/anti-Ri)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Paraneoplastic; breast, SCLC</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-CV2/CRMP5</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Paraneoplastic; SCLC, thymoma</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-amphiphysin</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Paraneoplastic; breast, SCLC; stiff-person overlap</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-Ma2/Ta</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Paraneoplastic limbic encephalitis; testicular germ cell tumor</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-SOX1</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>SCLC-associated; Lambert-Eaton overlap</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-Kelch-like protein 11 (KLHL11)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Testicular seminoma; brainstem/cerebellar syndrome</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-GlyR (glycine receptor)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Progressive encephalomyelitis with rigidity and myoclonus (PERM)</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-mGluR5</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Ophelia syndrome; Hodgkin lymphoma</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-mGluR1</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Cerebellar ataxia; Hodgkin lymphoma</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-neurexin-3-alpha</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Rapid-onset encephalitis; seizures; confusion</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-D2R (dopamine-2 receptor)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Basal ganglia encephalitis; movement disorders</td>
<td>Negative</td>
</tr>
<tr>
<td>Paraneoplastic evaluation panel (comprehensive)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>If standard panels negative and paraneoplastic suspected</td>
<td>All negative</td>
</tr>
<tr>
<td>14-3-3 protein (CSF)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Prion disease mimic; rapidly progressive dementia</td>
<td>Negative</td>
</tr>
<tr>
<td>RT-QuIC (CSF)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Prion disease exclusion in rapidly progressive cases</td>
<td>Negative</td>
</tr>
<tr>
<td>Next-generation sequencing (CSF metagenomics)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Occult infection when standard testing negative</td>
<td>No pathogens detected</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="2-diagnostic-imaging-studies">2. DIAGNOSTIC IMAGING &amp; STUDIES<a class="headerlink" href="#2-diagnostic-imaging-studies" title="Permanent link">&para;</a></h2>
<h3 id="2a-essentialfirst-line">2A. Essential/First-line<a class="headerlink" href="#2a-essentialfirst-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT head without contrast</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Immediate (ED triage)</td>
<td>Rule out mass, hemorrhage, hydrocephalus</td>
<td>None significant</td>
</tr>
<tr>
<td>MRI brain with and without contrast</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Within 24h</td>
<td>Mesial temporal T2/FLAIR hyperintensity (limbic encephalitis); cortical/subcortical signal changes; leptomeningeal enhancement</td>
<td>GFR &lt;30, gadolinium allergy, pacemaker</td>
</tr>
<tr>
<td>EEG (routine or continuous)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Within 24h; continuous if ICU or altered consciousness</td>
<td>Extreme delta brush (anti-NMDAR); focal/generalized slowing; epileptiform discharges; subclinical seizures</td>
<td>None significant</td>
</tr>
<tr>
<td>ECG (12-lead)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Immediate</td>
<td>Autonomic dysfunction; arrhythmia; QTc prolongation (medication safety)</td>
<td>None</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Immediate</td>
<td>Mediastinal mass (thymoma); pulmonary mass (SCLC)</td>
<td>Pregnancy (relative)</td>
</tr>
<tr>
<td>Continuous telemetry</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Continuous in hospital</td>
<td>Arrhythmia from autonomic instability</td>
<td>None</td>
</tr>
</tbody>
</table>
<h3 id="2b-extended">2B. Extended<a class="headerlink" href="#2b-extended" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI spine (cervical and thoracic) with and without contrast</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Within 48-72h</td>
<td>Concurrent myelitis; overlap syndromes</td>
<td>GFR &lt;30, gadolinium allergy</td>
</tr>
<tr>
<td>CT chest/abdomen/pelvis with contrast</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Within 48h</td>
<td>Occult malignancy: thymoma, lung cancer, ovarian teratoma, lymphoma</td>
<td>Contrast allergy, renal insufficiency</td>
</tr>
<tr>
<td>Pelvic/transvaginal ultrasound (females)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Within 48h</td>
<td>Ovarian teratoma (anti-NMDAR)</td>
<td>None significant</td>
</tr>
<tr>
<td>Testicular ultrasound (males &lt;50)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Within 48h</td>
<td>Testicular germ cell tumor (anti-Ma2, KLHL11)</td>
<td>None significant</td>
</tr>
<tr>
<td>FDG-PET/CT (whole body)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Within 1-2 weeks</td>
<td>Occult malignancy not seen on CT; FDG-avid tumor</td>
<td>Uncontrolled diabetes, pregnancy</td>
</tr>
<tr>
<td>Video-EEG monitoring (prolonged)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>As needed</td>
<td>Characterize seizure semiology; subclinical seizures; extreme delta brush pattern</td>
<td>None</td>
</tr>
<tr>
<td>FDG-PET brain</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>Within 1-2 weeks</td>
<td>Mesial temporal hypermetabolism (early) or hypometabolism (late); cortical metabolic changes</td>
<td>Same as PET/CT</td>
</tr>
</tbody>
</table>
<h3 id="2c-rarespecialized">2C. Rare/Specialized<a class="headerlink" href="#2c-rarespecialized" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI brain with epilepsy protocol</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>If seizures refractory</td>
<td>Subtle cortical lesions; hippocampal sclerosis</td>
<td>Gadolinium contraindications</td>
</tr>
<tr>
<td>Brain biopsy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td>Last resort</td>
<td>Inflammatory infiltrate; exclusion of other pathology</td>
<td>Coagulopathy, inaccessible location</td>
</tr>
<tr>
<td>CT-guided biopsy (tumor)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>After tumor identified</td>
<td>Histopathological confirmation</td>
<td>Coagulopathy, tumor location</td>
</tr>
<tr>
<td>Mammography/breast MRI</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>If AMPA, amphiphysin positive</td>
<td>Breast malignancy</td>
<td>Implants (relative for MRI)</td>
</tr>
<tr>
<td>Polysomnography</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">-</td>
<td>If IgLON5 suspected</td>
<td>REM/NREM parasomnias; sleep disordered breathing</td>
<td>None significant</td>
</tr>
</tbody>
</table>
<h3 id="lumbar-puncture">LUMBAR PUNCTURE<a class="headerlink" href="#lumbar-puncture" title="Permanent link">&para;</a></h3>
<p><strong>Indication:</strong> Essential for diagnosis of autoimmune encephalitis; supports Graus 2016 criteria (CSF pleocytosis); CSF antibody testing more sensitive than serum for anti-NMDAR; rules out infectious encephalitis</p>
<p><strong>Timing:</strong> STAT/URGENT -- perform as soon as safely possible after CT head; do NOT delay for MRI</p>
<p><strong>Volume Required:</strong> 20-30 mL (large volume for comprehensive antibody and infectious testing)</p>
<table>
<thead>
<tr>
<th>Study</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th>Rationale</th>
<th>Target Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening pressure</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Elevated ICP assessment</td>
<td>10-20 cm H2O</td>
</tr>
<tr>
<td>Cell count with differential (tubes 1 and 4)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td>Lymphocytic pleocytosis supports autoimmune</td>
<td>WBC 5-80 (lymphocyte-predominant); RBC 0</td>
</tr>
<tr>
<td>Protein</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td>Mildly elevated in autoimmune; markedly elevated suggests infection/GBS</td>
<td>Normal to mildly elevated (usually &lt;100 mg/dL)</td>
</tr>
<tr>
<td>Glucose with paired serum glucose</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td>Low in infection/carcinomatous meningitis</td>
<td>Normal (&gt;60% of serum)</td>
</tr>
<tr>
<td>Gram stain and bacterial culture</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td>Rule out bacterial meningitis</td>
<td>No organisms</td>
</tr>
<tr>
<td>HSV 1/2 PCR</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td>Rule out HSV encephalitis (most important mimic)</td>
<td>Negative</td>
</tr>
<tr>
<td>VZV PCR</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td>Varicella encephalitis</td>
<td>Negative</td>
</tr>
<tr>
<td>EBV PCR</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>EBV-associated encephalitis; lymphoma screen</td>
<td>Negative</td>
</tr>
<tr>
<td>CMV PCR</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Immunocompromised patients</td>
<td>Negative</td>
</tr>
<tr>
<td>HHV-6 PCR</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Post-transplant; limbic encephalitis mimic</td>
<td>Negative</td>
</tr>
<tr>
<td>Enterovirus PCR</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td>Viral meningitis/encephalitis</td>
<td>Negative</td>
</tr>
<tr>
<td>West Nile virus IgM/IgG</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Endemic areas; flaccid paralysis</td>
<td>Negative</td>
</tr>
<tr>
<td>Cryptococcal antigen</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Immunocompromised; chronic meningitis</td>
<td>Negative</td>
</tr>
<tr>
<td>VDRL (CSF)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Neurosyphilis</td>
<td>Negative</td>
</tr>
<tr>
<td>Oligoclonal bands (CSF AND paired serum)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Intrathecal IgG synthesis; MS/NMOSD overlap</td>
<td>May show CSF-specific bands</td>
</tr>
<tr>
<td>IgG index</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Intrathecal antibody synthesis</td>
<td>May be elevated</td>
</tr>
<tr>
<td>Cytology</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Carcinomatous/lymphomatous meningitis</td>
<td>Negative</td>
</tr>
<tr>
<td>Flow cytometry</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>CNS lymphoma</td>
<td>Normal</td>
</tr>
<tr>
<td><strong>Autoimmune encephalitis antibody panel (CSF)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td>NMDAR, LGI1, CASPR2, GABA-B, AMPA, DPPX -- CBA method</td>
<td>All negative</td>
</tr>
<tr>
<td><strong>Anti-NMDAR IgG (CSF)</strong></td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td>CSF more sensitive than serum for NMDAR</td>
<td>Negative</td>
</tr>
<tr>
<td>AFB culture and smear</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>TB meningitis if risk factors</td>
<td>Negative</td>
</tr>
<tr>
<td>Fungal culture</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Immunocompromised</td>
<td>Negative</td>
</tr>
</tbody>
</table>
<p><strong>Special Handling:</strong> Send minimum 2 mL CSF to each reference lab. Anti-NMDAR CSF testing is more sensitive than serum -- ALWAYS send CSF. Antibody results take 1-3 weeks. Cytology requires rapid transport (&lt;1 hour). Store extra CSF (frozen at -20C) for future testing.</p>
<p><strong>Contraindications:</strong> Elevated ICP without imaging (get CT first), coagulopathy (INR &gt;1.5, platelets &lt;50K), skin infection at LP site, posterior fossa mass with risk of herniation</p>
<hr />
<h2 id="3-treatment">3. TREATMENT<a class="headerlink" href="#3-treatment" title="Permanent link">&para;</a></h2>
<h3 id="3a-acuteemergent">3A. Acute/Emergent<a class="headerlink" href="#3a-acuteemergent" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Empiric acyclovir IV (until HSV ruled out)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>10 mg/kg IV q8h; continue until HSV PCR negative x2 (48h apart) or alternative diagnosis confirmed</td>
<td>Renal impairment (adjust dose); adequate hydration required</td>
<td>Renal function daily; hydration status; crystal nephropathy prevention</td>
</tr>
<tr>
<td>Empiric antibiotics (if bacterial meningitis not excluded)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Ceftriaxone 2g IV q12h + vancomycin 15-20 mg/kg IV q8-12h + dexamethasone 0.15 mg/kg q6h x 4 days</td>
<td>Per individual drug allergies</td>
<td>Cultures; clinical response; renal function; vancomycin troughs</td>
</tr>
<tr>
<td>Lorazepam (acute seizure)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>0.1 mg/kg IV (max 4 mg/dose); may repeat x1 in 5 minutes</td>
<td>Respiratory depression; acute narrow-angle glaucoma</td>
<td>Respiratory status; sedation level; airway patency</td>
</tr>
<tr>
<td>Midazolam (if no IV access)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>10 mg IM (adults &gt;40 kg) or 0.2 mg/kg intranasal</td>
<td>Respiratory depression</td>
<td>Same as lorazepam</td>
</tr>
<tr>
<td>Lorazepam (catatonia challenge)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>1-2 mg IV; observe 15-30 min for response; if improvement, continue 1-2 mg IV/PO q4-8h (up to 8-24 mg/day)</td>
<td>Respiratory compromise; prior paradoxical response</td>
<td>Bush-Francis Catatonia Rating Scale; respiratory status; sedation</td>
</tr>
</tbody>
</table>
<p><em>Note: Initiate empiric acyclovir and antibiotics IMMEDIATELY. Do NOT delay antimicrobials for LP. Start immunotherapy as soon as autoimmune encephalitis is clinically suspected -- do NOT wait for antibody results.</em></p>
<h3 id="3b-first-line-immunotherapy">3B. First-Line Immunotherapy<a class="headerlink" href="#3b-first-line-immunotherapy" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylprednisolone IV</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>1000 mg IV daily x 5 days; infuse over 1-2 hours</td>
<td>Active untreated infection; uncontrolled diabetes; psychosis from steroids</td>
<td>Glucose q6h (target &lt;180); BP; mood/sleep; I/O; GI prophylaxis</td>
</tr>
<tr>
<td>Omeprazole (GI prophylaxis during steroids)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>40 mg IV/PO daily during steroid course</td>
<td>PPI allergy</td>
<td>None routine</td>
</tr>
<tr>
<td>Insulin sliding scale</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Per protocol if glucose &gt;180 mg/dL</td>
<td>Hypoglycemia risk</td>
<td>Glucose q6h; adjust per response</td>
</tr>
<tr>
<td>IVIG (intravenous immunoglobulin)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>0.4 g/kg/day IV x 5 days (total 2 g/kg); infuse per weight-based protocol; premedicate with acetaminophen, diphenhydramine</td>
<td>IgA deficiency (anaphylaxis risk); recent thromboembolic event; renal failure</td>
<td>Renal function daily; headache (aseptic meningitis); thrombosis; volume overload; check IgA level before first dose</td>
</tr>
<tr>
<td>Plasmapheresis (PLEX)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange; albumin replacement</td>
<td>Hemodynamic instability; sepsis; coagulopathy; poor vascular access</td>
<td>BP during exchanges; electrolytes (Ca, K, Mg); coagulation (fibrinogen); line site; citrate reactions</td>
</tr>
</tbody>
</table>
<p><em>Note: Methylprednisolone is typically started first (often in combination with IVIG or PLEX). IVIG and PLEX are considered equivalent first-line therapies and should be started concurrently or within days of steroids if clinical suspicion is high. For anti-NMDAR encephalitis, combination of all three first-line agents is common. PLEX may be preferred if rapid deterioration; IVIG may be preferred if hemodynamic instability or vascular access issues.</em></p>
<h3 id="3c-second-line-immunotherapy">3C. Second-Line Immunotherapy<a class="headerlink" href="#3c-second-line-immunotherapy" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rituximab</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>375 mg/m2 IV weekly x 4 doses OR 1000 mg IV x 2 doses (day 0 and day 14); premedicate with methylprednisolone 100 mg, acetaminophen, diphenhydramine</td>
<td>Active hepatitis B; severe active infection; live vaccines within 4 weeks</td>
<td>Hepatitis B serology (before first dose); CBC with differential q2-4 weeks; immunoglobulin levels q3 months; CD19/CD20 B-cell counts; infusion reactions; PML surveillance</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>750 mg/m2 IV monthly x 6 cycles; pre-hydrate with 1L NS; administer with MESNA (uroprotection)</td>
<td>Pregnancy; active infection; bone marrow failure; bladder outlet obstruction</td>
<td>CBC weekly x 4 weeks after each cycle (nadir day 10-14); urinalysis; BMP; LFTs; fertility counseling; hemorrhagic cystitis prevention</td>
</tr>
<tr>
<td>Tocilizumab (third-line)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td>8 mg/kg IV every 4 weeks (max 800 mg/dose)</td>
<td>Active infection; hepatic impairment (ALT &gt;5x ULN); diverticulitis; concurrent live vaccines</td>
<td>CBC, LFTs, lipids q4-8 weeks; infection surveillance; GI perforation risk; neutropenia</td>
</tr>
<tr>
<td>Bortezomib (third-line)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td>1.3 mg/m2 SC/IV on days 1, 4, 8, 11 of 21-day cycles x 4-6 cycles</td>
<td>Severe hepatic impairment; peripheral neuropathy grade 2+</td>
<td>CBC; peripheral neuropathy assessment (dose-reduce or hold if worsens); herpes zoster prophylaxis (acyclovir 400 mg BID)</td>
</tr>
<tr>
<td>Repeated IVIG or PLEX cycles</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>IVIG 0.4 g/kg/day x 5 days (repeat q4 weeks) or PLEX 5 exchanges (repeat as needed)</td>
<td>Same as first-line</td>
<td>Same as first-line</td>
</tr>
<tr>
<td>Oral prednisone taper (following IV methylprednisolone)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>1 mg/kg/day (max 60 mg) x 2 weeks; taper by 10 mg/week to 20 mg; then taper by 5 mg/week to discontinuation OR low-dose maintenance</td>
<td>Active infection; uncontrolled diabetes; avascular necrosis</td>
<td>Glucose; BP; bone density if prolonged; mood; weight; adrenal insufficiency on taper</td>
</tr>
</tbody>
</table>
<p><em>Note: Second-line therapy should be initiated if no improvement within 2 weeks of first-line therapy OR if clinically worsening despite first-line treatment. For anti-NMDAR encephalitis, early escalation to rituximab is associated with improved outcomes. Rituximab is generally preferred over cyclophosphamide given better safety profile. Third-line agents (tocilizumab, bortezomib) reserved for refractory cases failing rituximab/cyclophosphamide.</em></p>
<h3 id="3d-seizure-management">3D. Seizure Management<a class="headerlink" href="#3d-seizure-management" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam (first-line ASM)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Load: 1000-1500 mg IV; Maintenance: 500-1500 mg IV/PO BID (max 3000 mg/day)</td>
<td>Renal impairment (adjust dose per CrCl)</td>
<td>Behavioral changes (rage, irritability); suicidality; renal function</td>
</tr>
<tr>
<td>Lacosamide (second-line ASM)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Load: 200-400 mg IV; Maintenance: 100-200 mg IV/PO BID (max 400 mg/day)</td>
<td>Second/third degree AV block; severe hepatic impairment</td>
<td>ECG (PR prolongation); dizziness; cardiac monitoring during load</td>
</tr>
<tr>
<td>Valproic acid</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Load: 20-40 mg/kg IV (max rate 6 mg/kg/min); Maintenance: 250-500 mg IV/PO q8h (target level 50-100 mcg/mL)</td>
<td>Pregnancy (teratogenic -- Category X); hepatic disease; urea cycle disorders; mitochondrial disease (POLG)</td>
<td>LFTs; ammonia; CBC (thrombocytopenia); drug level; pancreatitis</td>
</tr>
<tr>
<td>Brivaracetam</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Load: 100 mg IV; Maintenance: 50-100 mg IV/PO BID (max 200 mg/day)</td>
<td>Hepatic impairment (reduce dose)</td>
<td>Behavioral changes; sedation</td>
</tr>
<tr>
<td>Clobazam</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Start 5-10 mg BID; titrate to 20-40 mg/day in divided doses</td>
<td>Severe hepatic impairment; myasthenia gravis</td>
<td>Sedation; CYP2C19 poor metabolizers (reduce dose); tolerance; dependence</td>
</tr>
<tr>
<td>Phenytoin/fosphenytoin (refractory)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Fosphenytoin: 20 mg PE/kg IV (max rate 150 mg PE/min); Maintenance: 5-7 mg/kg/day divided BID-TID (target level 10-20 mcg/mL)</td>
<td>AV block; bradycardia</td>
<td>Continuous cardiac monitoring during load; drug level; purple glove syndrome (peripheral IV); gingival hyperplasia</td>
</tr>
<tr>
<td>Phenobarbital (refractory)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td>Load: 15-20 mg/kg IV (max rate 60 mg/min); Maintenance: 1-3 mg/kg/day (target level 15-40 mcg/mL)</td>
<td>Severe respiratory depression; porphyria</td>
<td>Respiratory depression; sedation; hypotension; drug level</td>
</tr>
<tr>
<td>Midazolam infusion (refractory SE)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Bolus: 0.2 mg/kg IV; Infusion: 0.1-2.0 mg/kg/hr; titrate to EEG burst suppression</td>
<td>Unprotected airway (requires intubation)</td>
<td>Continuous EEG; respiratory status; hemodynamics; tachyphylaxis</td>
</tr>
<tr>
<td>Propofol infusion (refractory SE)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Bolus: 1-2 mg/kg IV; Infusion: 20-80 mcg/kg/min (max 5 mg/kg/hr to avoid PRIS)</td>
<td>Propofol infusion syndrome risk (prolonged use &gt;48h at high doses); egg/soy allergy</td>
<td>Continuous EEG; triglycerides q48h; CPK; lactate; hemodynamics; PRIS surveillance</td>
</tr>
<tr>
<td>Ketamine infusion (super-refractory SE)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Bolus: 1-3 mg/kg IV; Infusion: 0.5-5 mg/kg/hr</td>
<td>Uncontrolled hypertension; raised ICP (relative)</td>
<td>Continuous EEG; BP; HR; hepatic function; laryngospasm risk</td>
</tr>
</tbody>
</table>
<p><em>Note: Seizures in autoimmune encephalitis are driven by antibody-mediated mechanisms -- immunotherapy is the definitive seizure treatment. ASMs control acute seizures but will not resolve the underlying cause. Avoid carbamazepine/oxcarbazepine in LGI1 encephalitis (may worsen hyponatremia). Levetiracetam and lacosamide are preferred first-line ASMs given favorable drug interaction profiles with immunotherapy.</em></p>
<h3 id="3e-psychiatric-symptom-management">3E. Psychiatric Symptom Management<a class="headerlink" href="#3e-psychiatric-symptom-management" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haloperidol (acute agitation)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>0.5-2 mg IV/IM q4-6h PRN (lowest effective dose); max 20 mg/day</td>
<td>QTc &gt;500 ms; Parkinson disease; prior NMS</td>
<td>ECG (QTc); EPS; NMS surveillance; temperature; CPK if NMS suspected</td>
</tr>
<tr>
<td>Olanzapine (agitation/psychosis)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>2.5-5 mg PO/IM BID (start low); max 20 mg/day</td>
<td>QTc prolongation; metabolic syndrome</td>
<td>Glucose; lipids; QTc; weight; sedation; EPS</td>
</tr>
<tr>
<td>Quetiapine (psychosis/insomnia)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Start 25-50 mg qHS; titrate to 200-400 mg/day in divided doses</td>
<td>QTc prolongation; severe hepatic impairment</td>
<td>QTc; metabolic parameters; orthostatic BP; sedation</td>
</tr>
<tr>
<td>Lorazepam (catatonia -- first-line)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Start 1-2 mg IV/PO; if response, 1-2 mg q4-8h (escalate to 8-24 mg/day as needed for catatonia)</td>
<td>Respiratory compromise (high doses)</td>
<td>Bush-Francis Catatonia Rating Scale; respiratory rate; sedation; airway</td>
</tr>
<tr>
<td>Dexmedetomidine (agitation in ICU)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Load: 1 mcg/kg IV over 10 min (optional); Infusion: 0.2-0.7 mcg/kg/hr (max 1.5 mcg/kg/hr)</td>
<td>Severe bradycardia; advanced heart block</td>
<td>HR (bradycardia); BP (hypotension); sedation level (RASS)</td>
</tr>
<tr>
<td>Valproic acid (mood stabilization/agitation)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>250-500 mg PO BID; titrate to level 50-100 mcg/mL (dual benefit: mood + seizure)</td>
<td>Pregnancy; hepatic disease</td>
<td>LFTs; ammonia; CBC; drug level</td>
</tr>
<tr>
<td>Melatonin (sleep-wake disturbance)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>3-10 mg PO qHS</td>
<td>None significant</td>
<td>Sleep quality; no significant drug interactions</td>
</tr>
<tr>
<td>Trazodone (insomnia)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>25-100 mg PO qHS</td>
<td>Concurrent MAOIs; QTc prolongation</td>
<td>Orthostatic hypotension; priapism (rare); sedation</td>
</tr>
<tr>
<td>Electroconvulsive therapy (ECT) (refractory catatonia)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td>Per psychiatry protocol; typically 3x/week</td>
<td>Pheochromocytoma; raised ICP (relative)</td>
<td>Anesthesia monitoring; cognitive function; post-procedure seizure threshold</td>
</tr>
</tbody>
</table>
<p><em>Note: CAUTION with antipsychotics in autoimmune encephalitis -- patients (especially anti-NMDAR) are highly susceptible to neuroleptic malignant syndrome (NMS) and EPS. Use LOWEST effective doses. Benzodiazepines (lorazepam) are first-line for catatonia and agitation. Catatonia may be present in up to 40% of anti-NMDAR cases. If catatonia does not respond to lorazepam, consider ECT before escalating antipsychotics. Psychiatric symptoms in AE are driven by antibody-mediated mechanisms -- immunotherapy is the definitive treatment.</em></p>
<h3 id="3f-icu-specific-treatments">3F. ICU-Specific Treatments<a class="headerlink" href="#3f-icu-specific-treatments" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intubation and mechanical ventilation</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>RSI: avoid succinylcholine if hyperkalemia risk; maintain normocapnia</td>
<td>As per standard airway management</td>
<td>Ventilator parameters; ABG; daily SBT when appropriate</td>
</tr>
<tr>
<td>Labetalol IV (autonomic hypertensive crisis)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>10-20 mg IV q10-15min PRN; or infusion 0.5-2 mg/min; target SBP &lt;180</td>
<td>Severe bradycardia; AV block; decompensated CHF; asthma</td>
<td>Continuous BP; HR; I/O</td>
</tr>
<tr>
<td>Esmolol IV (autonomic tachycardia)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Bolus: 500 mcg/kg over 1 min; Infusion: 50-200 mcg/kg/min</td>
<td>Severe bradycardia; decompensated CHF; cardiogenic shock</td>
<td>Continuous HR/BP; ECG</td>
</tr>
<tr>
<td>Atropine (autonomic bradycardia)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>0.5-1 mg IV q3-5min (max 3 mg total)</td>
<td>Tachycardia; thyrotoxicosis</td>
<td>HR; rhythm</td>
</tr>
<tr>
<td>Isoproterenol drip (severe autonomic bradycardia)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>2-10 mcg/min IV infusion; titrate to HR &gt;60</td>
<td>Tachyarrhythmia; digoxin toxicity</td>
<td>Continuous ECG; HR; BP</td>
</tr>
<tr>
<td>Temporary transvenous pacemaker</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Per cardiology if pharmacologic measures fail</td>
<td>Active infection at insertion site</td>
<td>Capture; sensing; threshold checks</td>
</tr>
<tr>
<td>Norepinephrine (autonomic hypotension)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>0.1-0.5 mcg/kg/min IV; titrate to MAP &gt;65</td>
<td>Peripheral ischemia risk at high doses</td>
<td>Arterial line; MAP; lactate; urine output</td>
</tr>
<tr>
<td>DVT prophylaxis (enoxaparin)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>40 mg SC daily (adjust for renal function: 30 mg SC daily if CrCl &lt;30)</td>
<td>Active bleeding; HIT; severe thrombocytopenia</td>
<td>Platelet count; anti-Xa if renal impairment; bleeding signs</td>
</tr>
<tr>
<td>Temperature management (hyperthermia)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">STAT</td>
<td>Targeted temperature: 36-37C; cooling blankets; acetaminophen 1g IV/PO q6h PRN</td>
<td>Avoid overcooling; avoid shivering (increases metabolic demand)</td>
<td>Continuous temperature; shivering assessment (BSAS)</td>
</tr>
<tr>
<td>Sodium correction (hyponatremia -- LGI1)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>If Na &lt;125: 3% NaCl 100-150 mL IV over 10-20 min (repeat up to 3x); Target correction: 4-6 mEq/L in first 6h, max 8 mEq/L in 24h</td>
<td>Avoid overcorrection (osmotic demyelination risk)</td>
<td>Sodium q2-4h during correction; urine output; neurologic status</td>
</tr>
<tr>
<td>Fludrocortisone (chronic hyponatremia -- LGI1)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>0.05-0.2 mg PO daily</td>
<td>CHF; hypertension</td>
<td>Sodium; potassium; BP; edema</td>
</tr>
<tr>
<td>Fluid restriction (SIADH-related hyponatremia)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td>Restrict to 1-1.2 L/day if SIADH suspected (LGI1)</td>
<td>Dehydration risk</td>
<td>Sodium; I/O; daily weight; urine osmolality</td>
</tr>
</tbody>
</table>
<p><em>Note: Central hypoventilation occurs in anti-NMDAR encephalitis and may require prolonged mechanical ventilation (weeks to months). Autonomic instability (tachycardia/bradycardia alternating, blood pressure lability, central hyperthermia, cardiac dysrhythmias) is a hallmark of severe anti-NMDAR encephalitis. LGI1 encephalitis frequently causes SIADH-related hyponatremia. Do NOT over-correct sodium (risk of osmotic demyelination).</em></p>
<h3 id="3g-long-term-immunosuppression-maintenance">3G. Long-Term Immunosuppression / Maintenance<a class="headerlink" href="#3g-long-term-immunosuppression-maintenance" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mycophenolate mofetil (CellCept)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Start 500 mg PO BID; increase to 1000 mg PO BID over 2-4 weeks (target 1500-3000 mg/day)</td>
<td>Pregnancy (Category D -- teratogenic); active infection</td>
<td>CBC q2 weeks x 3 months, then monthly; LFTs; GI symptoms; infection surveillance; pregnancy prevention</td>
</tr>
<tr>
<td>Azathioprine (Imuran)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Start 50 mg PO daily; increase by 50 mg every 2 weeks to target 2-3 mg/kg/day</td>
<td>TPMT deficiency (check before starting); pregnancy (relative)</td>
<td>TPMT genotype/activity before starting; CBC q2 weeks x 2 months, then monthly; LFTs; pancreatitis</td>
</tr>
<tr>
<td>Rituximab (maintenance)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>500-1000 mg IV every 6 months; re-dose based on CD19/CD20 B-cell repopulation or clinical relapse</td>
<td>Active hepatitis B; severe active infection</td>
<td>CD19/CD20 counts q3 months; immunoglobulin levels q3-6 months; hepatitis B surveillance; infection monitoring; PML surveillance</td>
</tr>
<tr>
<td>Oral prednisone (low-dose maintenance)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>5-10 mg PO daily; aim to taper off within 3-6 months if on steroid-sparing agent</td>
<td>Poorly controlled diabetes; active infection; avascular necrosis</td>
<td>Glucose; BP; bone density (DEXA if &gt;3 months); weight; mood; cataracts; adrenal assessment on taper</td>
</tr>
<tr>
<td>IVIG (maintenance)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>0.4 g/kg IV every 4 weeks OR 1-2 g/kg IV every 4-6 weeks (adjust per response)</td>
<td>IgA deficiency; thromboembolic history</td>
<td>Renal function; headache; IgG trough levels; infusion reactions</td>
</tr>
<tr>
<td>Calcium + Vitamin D (bone protection with steroids)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Calcium 1000-1200 mg/day + Vitamin D 1000-2000 IU/day</td>
<td>Hypercalcemia; kidney stones</td>
<td>25-OH Vitamin D level; calcium; DEXA baseline if anticipated steroid use &gt;3 months</td>
</tr>
</tbody>
</table>
<p><em>Note: Long-term immunosuppression is guided by antibody subtype, relapse risk, and tumor status. Anti-NMDAR encephalitis has ~12-20% relapse rate. Rituximab maintenance is most commonly used for relapse prevention. Mycophenolate and azathioprine are steroid-sparing alternatives. Monitor for immunosuppression-related complications (infection, malignancy). Duration of maintenance therapy is individualized -- typically minimum 2 years; some patients require indefinite treatment.</em></p>
<hr />
<h2 id="4-other-recommendations">4. OTHER RECOMMENDATIONS<a class="headerlink" href="#4-other-recommendations" title="Permanent link">&para;</a></h2>
<h3 id="4a-referrals-consults">4A. Referrals &amp; Consults<a class="headerlink" href="#4a-referrals-consults" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurology (autoimmune/neuroimmunology)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>All suspected autoimmune encephalitis cases; immunotherapy management</td>
</tr>
<tr>
<td>Epilepsy/EEG service</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
<td>Seizure management; continuous EEG monitoring; extreme delta brush interpretation</td>
</tr>
<tr>
<td>Psychiatry</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Psychiatric manifestations (psychosis, catatonia, agitation); antipsychotic management; NMS risk</td>
</tr>
<tr>
<td>Critical care/ICU</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td>Autonomic instability; respiratory failure; refractory status epilepticus; altered consciousness</td>
</tr>
<tr>
<td>Gynecologic oncology (females with anti-NMDAR)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td>Ovarian teratoma screening and surgical resection</td>
</tr>
<tr>
<td>Oncology</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
<td>Any identified malignancy; tumor screening guidance; chemotherapy planning</td>
</tr>
<tr>
<td>Urology (males &lt;50 with anti-Ma2/KLHL11)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Testicular germ cell tumor screening</td>
</tr>
<tr>
<td>Hematology/apheresis</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td>PLEX coordination; catheter placement</td>
</tr>
<tr>
<td>Physical therapy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Motor rehabilitation; gait training; fall prevention</td>
</tr>
<tr>
<td>Occupational therapy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>ADL assessment; cognitive rehabilitation; adaptive strategies</td>
</tr>
<tr>
<td>Speech-language pathology</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td>Swallowing evaluation; language/communication rehabilitation; cognitive-linguistic therapy</td>
</tr>
<tr>
<td>Neuropsychology</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Formal cognitive assessment; rehabilitation planning; serial monitoring</td>
</tr>
<tr>
<td>Social work</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Family support; insurance navigation; disability resources; long-term care planning</td>
</tr>
<tr>
<td>Rehabilitation medicine</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Comprehensive inpatient or outpatient rehab program coordination</td>
</tr>
<tr>
<td>Palliative care</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td>Refractory cases; prolonged ICU stay; family support; goals of care discussion</td>
</tr>
<tr>
<td>Infectious disease</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">URGENT</td>
<td>Rule out infection; antimicrobial guidance; post-immunosuppression infection management</td>
</tr>
<tr>
<td>Endocrinology</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">-</td>
<td>Steroid-induced hyperglycemia management; thyroid evaluation if Hashimoto suspected</td>
</tr>
</tbody>
</table>
<h3 id="4b-patientfamily-instructions">4B. Patient/Family Instructions<a class="headerlink" href="#4b-patientfamily-instructions" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Return to ED immediately for new seizures, sudden behavioral changes, fever, difficulty breathing, or loss of consciousness</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Autoimmune encephalitis is a treatable condition -- recovery may be slow (months to years) but significant improvement is expected with appropriate immunotherapy</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Do NOT drive until seizure-free for state-mandated period AND cleared by neurology</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Keep seizure diary (date, time, type, duration, triggers)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Behavioral and psychiatric symptoms are part of the disease, not a primary psychiatric disorder -- immunotherapy is the treatment</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Report any signs of infection (fever &gt;100.4F, cough, dysuria, rash) immediately while on immunotherapy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Avoid live vaccines while on immunosuppressive therapy (inform all physicians of immunosuppression status)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Do not stop anti-seizure medications abruptly</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Avoid alcohol and recreational drugs (lower seizure threshold, interact with medications)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Pregnancy must be avoided during immunotherapy; discuss contraception with neurology and OB/GYN</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Expect gradual improvement -- anti-NMDAR recovery typically occurs in reverse order of symptom onset (psychiatric symptoms resolve last)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Cognitive rehabilitation exercises as directed by speech and occupational therapy</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Safety modifications at home (remove sharp objects, secure stairways, fall prevention)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Medical alert bracelet recommended (autoimmune encephalitis, seizure risk, immunosuppressed)</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
<tr>
<td>Follow-up appointments are critical -- relapse monitoring requires regular visits</td>
<td style="text-align: center;">-</td>
<td style="text-align: center;">Y</td>
<td style="text-align: center;">Y</td>
</tr>
</tbody>
</table>
<h3 id="4c-tumor-screening-protocols-by-antibody">4C. Tumor Screening Protocols by Antibody<a class="headerlink" href="#4c-tumor-screening-protocols-by-antibody" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Antibody</th>
<th>Associated Tumor(s)</th>
<th>Screening Protocol</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-NMDAR</td>
<td>Ovarian teratoma (females, especially 12-45 years); rarely other tumors</td>
<td>Pelvic MRI or transvaginal US; CT chest/abdomen/pelvis</td>
<td>At diagnosis; repeat q6 months x 2 years if initially negative</td>
</tr>
<tr>
<td>Anti-LGI1</td>
<td>Thymoma (~5-10%)</td>
<td>CT chest with contrast</td>
<td>At diagnosis; repeat if relapse</td>
</tr>
<tr>
<td>Anti-CASPR2</td>
<td>Thymoma (~20-30%)</td>
<td>CT chest with contrast</td>
<td>At diagnosis; repeat if relapse</td>
</tr>
<tr>
<td>Anti-GABA-B</td>
<td>Small cell lung cancer (~50%)</td>
<td>CT chest; FDG-PET/CT if CT negative</td>
<td>At diagnosis; q6 months x 4 years</td>
</tr>
<tr>
<td>Anti-AMPA</td>
<td>Thymoma, lung cancer, breast cancer</td>
<td>CT chest/abdomen/pelvis; mammography; FDG-PET/CT</td>
<td>At diagnosis; q6 months x 4 years</td>
</tr>
<tr>
<td>Anti-DPPX</td>
<td>B-cell lymphoma (rare)</td>
<td>CT chest/abdomen/pelvis; FDG-PET if suspected</td>
<td>At diagnosis</td>
</tr>
<tr>
<td>Anti-Ma2/Ta</td>
<td>Testicular germ cell tumor (young males); lung cancer (older patients)</td>
<td>Testicular US (males &lt;50); CT chest; FDG-PET/CT</td>
<td>At diagnosis; q6 months x 4 years</td>
</tr>
<tr>
<td>Anti-Hu (ANNA-1)</td>
<td>Small cell lung cancer (&gt;90%)</td>
<td>CT chest; FDG-PET/CT</td>
<td>At diagnosis; q6 months x 4 years</td>
</tr>
<tr>
<td>Anti-CV2/CRMP5</td>
<td>SCLC; thymoma</td>
<td>CT chest; FDG-PET/CT</td>
<td>At diagnosis; q6 months x 4 years</td>
</tr>
<tr>
<td>Anti-amphiphysin</td>
<td>Breast cancer; SCLC</td>
<td>Mammography/breast MRI; CT chest</td>
<td>At diagnosis; q6 months x 4 years</td>
</tr>
<tr>
<td>Anti-KLHL11</td>
<td>Testicular seminoma</td>
<td>Testicular US; FDG-PET/CT</td>
<td>At diagnosis; repeat if relapse</td>
</tr>
</tbody>
</table>
<p><em>Note: Tumor resection is critical for treatment response -- immunotherapy alone may be insufficient if underlying tumor is not removed. If initial tumor screen is negative but paraneoplastic antibody is positive, repeat imaging q6 months x 4 years. Consider FDG-PET/CT if CT is negative and clinical suspicion remains high.</em></p>
<hr />
<p>═══════════════════════════════════════════════════════════
SECTION B: REFERENCE (Expand as Needed)
═══════════════════════════════════════════════════════════</p>
<h2 id="5-differential-diagnosis">5. DIFFERENTIAL DIAGNOSIS<a class="headerlink" href="#5-differential-diagnosis" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Alternative Diagnosis</th>
<th>Key Distinguishing Features</th>
<th>Tests to Differentiate</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSV encephalitis</td>
<td>Acute fever, temporal lobe hemorrhagic necrosis, CSF lymphocytic pleocytosis with RBCs</td>
<td>HSV PCR (CSF); MRI temporal lobe changes; often more acute onset</td>
</tr>
<tr>
<td>Other viral encephalitis (EBV, CMV, HHV-6, enterovirus, West Nile)</td>
<td>Fever, CSF pleocytosis, specific exposure/season, immunocompromised status</td>
<td>Specific viral PCR/serology; CSF studies</td>
</tr>
<tr>
<td>Bacterial meningitis/encephalitis</td>
<td>Acute fever, meningismus, CSF neutrophilic pleocytosis, low glucose</td>
<td>CSF Gram stain, culture, procalcitonin, bacterial PCR</td>
</tr>
<tr>
<td>Neurosyphilis</td>
<td>Cognitive decline, psychiatric symptoms, Argyll Robertson pupils, positive serology</td>
<td>RPR/VDRL; CSF VDRL; FTA-ABS</td>
</tr>
<tr>
<td>Prion disease (CJD)</td>
<td>Rapidly progressive dementia, myoclonus, akinetic mutism; cortical ribboning on MRI (DWI)</td>
<td>14-3-3 protein; RT-QuIC; MRI DWI cortical ribboning; EEG periodic discharges</td>
</tr>
<tr>
<td>CNS lymphoma</td>
<td>Progressive encephalopathy, mass lesion, periventricular enhancement, immunocompromised</td>
<td>CSF cytology/flow cytometry; FDG-PET; brain biopsy</td>
</tr>
<tr>
<td>CNS vasculitis</td>
<td>Headache, stroke-like episodes, multifocal infarcts, elevated ESR/CRP</td>
<td>Angiography; brain/leptomeningeal biopsy; ESR/CRP</td>
</tr>
<tr>
<td>Neurosarcoidosis</td>
<td>Cranial neuropathies, hypothalamic dysfunction, leptomeningeal enhancement</td>
<td>ACE level; chest CT (hilar adenopathy); biopsy</td>
</tr>
<tr>
<td>Hashimoto encephalopathy (SREAT)</td>
<td>Encephalopathy with very high anti-TPO; steroid-responsive; diagnosis of exclusion</td>
<td>Anti-TPO; anti-thyroglobulin; dramatic steroid response</td>
</tr>
<tr>
<td>Acute disseminated encephalomyelitis (ADEM)</td>
<td>Post-infectious/post-vaccination, multifocal large white matter lesions, encephalopathy</td>
<td>MRI pattern; MOG-IgG; monophasic course</td>
</tr>
<tr>
<td>NMO spectrum disorder (NMOSD)</td>
<td>Optic neuritis, longitudinally extensive myelitis, area postrema syndrome</td>
<td>AQP4-IgG; MRI pattern</td>
</tr>
<tr>
<td>Drug/toxin-induced encephalopathy</td>
<td>Temporal correlation with drug exposure; resolves with discontinuation</td>
<td>Urine drug screen; medication review; drug levels</td>
</tr>
<tr>
<td>Metabolic encephalopathy</td>
<td>Hepatic, uremic, thyroid, electrolyte disturbances</td>
<td>CMP; LFTs; ammonia; TSH; specific metabolic panels</td>
</tr>
<tr>
<td>Psychiatric disorder (new-onset psychosis, catatonia)</td>
<td>No CSF pleocytosis; normal MRI/EEG; isolated psychiatric symptoms (caution: AE can present as pure psychiatric)</td>
<td>LP mandatory to differentiate; EEG; MRI; antibody testing before assuming primary psychiatric</td>
</tr>
<tr>
<td>Seizure-related encephalopathy (post-ictal/non-convulsive SE)</td>
<td>Prolonged post-ictal confusion; non-convulsive status on EEG</td>
<td>Continuous EEG monitoring; resolves with ASM treatment</td>
</tr>
<tr>
<td>Neuro-Behcet disease</td>
<td>Oral/genital ulcers; brainstem predominance; CSF neutrophilic pleocytosis</td>
<td>Clinical criteria; pathergy test; HLA-B51</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="6-monitoring-parameters">6. MONITORING PARAMETERS<a class="headerlink" href="#6-monitoring-parameters" title="Permanent link">&para;</a></h2>
<h3 id="6a-acute-phase-monitoring-inpatient">6A. Acute Phase Monitoring (Inpatient)<a class="headerlink" href="#6a-acute-phase-monitoring-inpatient" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target/Threshold</th>
<th>Action if Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurologic examination (GCS, orientation, cranial nerves, motor, reflexes)</td>
<td>Q4-6h (ICU); Q8-12h (floor)</td>
<td>Stable or improving</td>
<td>If worsening: urgent re-imaging; escalate immunotherapy; consider ICU transfer</td>
</tr>
<tr>
<td>Modified Rankin Scale (mRS)</td>
<td>Baseline, then weekly</td>
<td>Improvement over weeks-months</td>
<td>Document trajectory; guide treatment escalation; long-term disability tracking</td>
</tr>
<tr>
<td>Bush-Francis Catatonia Rating Scale</td>
<td>Daily if catatonia features</td>
<td>Score decreasing with treatment</td>
<td>If not responding to lorazepam: increase dose; consider ECT; escalate immunotherapy</td>
</tr>
<tr>
<td>Blood glucose</td>
<td>Q6h during IV steroids</td>
<td>&lt;180 mg/dL</td>
<td>Insulin sliding scale; endocrine consult if persistent &gt;250</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Q1h (ICU); Q4h (floor)</td>
<td>SBP 100-180 mmHg; MAP &gt;65</td>
<td>Autonomic dysregulation: labetalol/esmolol for hypertension; norepinephrine for hypotension</td>
</tr>
<tr>
<td>Heart rate and rhythm</td>
<td>Continuous telemetry (ICU/floor)</td>
<td>HR 60-100; sinus rhythm</td>
<td>Autonomic instability: treat per protocol (3F); cardiology consult if sustained arrhythmia</td>
</tr>
<tr>
<td>Temperature</td>
<td>Q4h; continuous in ICU</td>
<td>36.0-37.5 C</td>
<td>Central hyperthermia: cooling measures; acetaminophen; rule out infection</td>
</tr>
<tr>
<td>Respiratory rate and NIF</td>
<td>Q4h (ICU); Q shift (floor)</td>
<td>RR &lt;20; NIF &gt;-30 cm H2O</td>
<td>NIF worsening toward -20: intubation; ICU transfer; evaluate for neuromuscular respiratory failure</td>
</tr>
<tr>
<td>Seizure log</td>
<td>Continuous</td>
<td>Decreasing frequency/severity</td>
<td>If increasing: escalate ASMs; re-assess immunotherapy; continuous EEG</td>
</tr>
<tr>
<td>EEG (continuous)</td>
<td>24-72h minimum; longer if ICU</td>
<td>Resolving extreme delta brush; no subclinical seizures</td>
<td>If persistent seizures: escalate per Section 3D</td>
</tr>
<tr>
<td>Sodium (Na)</td>
<td>Q6-12h (if LGI1 or hyponatremia)</td>
<td>Na &gt;130 mEq/L</td>
<td>Correct per protocol (3F); fluid restriction if SIADH</td>
</tr>
<tr>
<td>I/O and daily weight</td>
<td>Daily</td>
<td>Euvolemic</td>
<td>Adjust fluids; diuretics if fluid overload; free water restriction if SIADH</td>
</tr>
<tr>
<td>Renal function (BUN/Cr)</td>
<td>Daily during IVIG; q48h otherwise</td>
<td>Stable</td>
<td>Hold IVIG if Cr rising; hydration; nephrology consult</td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Q48h during immunotherapy; daily if on cyclophosphamide</td>
<td>WBC &gt;3.0; ANC &gt;1.5; Plt &gt;100</td>
<td>Hold immunotherapy if critically low; growth factor support; hematology consult</td>
</tr>
<tr>
<td>LFTs</td>
<td>Q48-72h during acute treatment</td>
<td>ALT/AST &lt;3x ULN</td>
<td>Dose adjustment or hold hepatotoxic medications</td>
</tr>
<tr>
<td>Fibrinogen (during PLEX)</td>
<td>Before each exchange</td>
<td>&gt;100 mg/dL</td>
<td>Hold PLEX if &lt;100; FFP replacement</td>
</tr>
</tbody>
</table>
<h3 id="6b-outpatientlong-term-monitoring">6B. Outpatient/Long-Term Monitoring<a class="headerlink" href="#6b-outpatientlong-term-monitoring" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target/Threshold</th>
<th>Action if Abnormal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurologic examination (cognition, behavior, seizures, motor)</td>
<td>Monthly x 6 months; then q3 months x 2 years; then q6 months</td>
<td>Sustained improvement; no new symptoms</td>
<td>If relapse: repeat LP/MRI; resume or escalate immunotherapy; re-screen for tumor</td>
</tr>
<tr>
<td>Modified Rankin Scale (mRS)</td>
<td>Each visit</td>
<td>Improving toward mRS 0-1</td>
<td>Document trajectory; adjust rehab goals; consider treatment escalation if plateau or decline</td>
</tr>
<tr>
<td>CASE score (Clinical Assessment Scale in Autoimmune Encephalitis)</td>
<td>Each visit</td>
<td>Improving score over time</td>
<td>Standardized outcome measure; guide treatment decisions</td>
</tr>
<tr>
<td>MRI brain with and without contrast</td>
<td>3-6 months post-treatment; then annually x 3 years</td>
<td>Stable or improved signal changes</td>
<td>New/worsening lesions: relapse workup; repeat antibody testing; escalate treatment</td>
</tr>
<tr>
<td>EEG (routine)</td>
<td>3-6 months post-treatment; as needed for seizure management</td>
<td>Improved background; no epileptiform activity</td>
<td>If persistent abnormality: continue/adjust ASMs; consider repeat immunotherapy</td>
</tr>
<tr>
<td>Serum antibody titers</td>
<td>q3-6 months x 2 years; then annually</td>
<td>Decreasing or negative</td>
<td>Rising titers may precede clinical relapse; increase surveillance; consider preemptive treatment</td>
</tr>
<tr>
<td>CBC with differential</td>
<td>Q2-4 weeks on mycophenolate/azathioprine; then monthly</td>
<td>WBC &gt;3.0; ANC &gt;1.5; Plt &gt;100</td>
<td>Hold/reduce immunosuppression; growth factor support</td>
</tr>
<tr>
<td>LFTs</td>
<td>Monthly x 3 months on azathioprine/mycophenolate; then q3 months</td>
<td>ALT/AST &lt;3x ULN</td>
<td>Dose reduction or switch agent</td>
</tr>
<tr>
<td>Immunoglobulin levels (IgG, IgA, IgM)</td>
<td>Q3-6 months on rituximab or other B-cell depletion</td>
<td>IgG &gt;400 mg/dL</td>
<td>Immunoglobulin replacement if recurrent infections with hypogammaglobulinemia</td>
</tr>
<tr>
<td>CD19/CD20 B-cell counts</td>
<td>Q3 months on rituximab</td>
<td>Depleted (&lt;1% B-cells) during active treatment</td>
<td>Guide re-dosing interval; B-cell repopulation may trigger relapse</td>
</tr>
<tr>
<td>TPMT activity/genotype</td>
<td>Once before starting azathioprine</td>
<td>Normal enzyme activity</td>
<td>Dose reduce or avoid azathioprine if intermediate/low TPMT</td>
</tr>
<tr>
<td>Tumor surveillance (per antibody type -- Section 4C)</td>
<td>Per protocol: q6 months x 2-4 years</td>
<td>No tumor identified</td>
<td>If tumor found: urgent oncology referral and surgical resection</td>
</tr>
<tr>
<td>Neuropsychological testing</td>
<td>Baseline (when able); 6 months; 12 months; annually</td>
<td>Improving cognitive domains</td>
<td>Guide cognitive rehabilitation; inform return to work/school planning</td>
</tr>
<tr>
<td>DEXA scan (bone density)</td>
<td>Baseline if steroids &gt;3 months; repeat q1-2 years</td>
<td>T-score &gt;-2.5</td>
<td>Bisphosphonate therapy; calcium/vitamin D optimization</td>
</tr>
<tr>
<td>ASM drug levels (if applicable)</td>
<td>Per drug-specific schedule; after dose changes</td>
<td>Therapeutic range</td>
<td>Adjust dose; assess adherence</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="7-disposition-criteria">7. DISPOSITION CRITERIA<a class="headerlink" href="#7-disposition-criteria" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Disposition</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discharge home</strong></td>
<td>Mild symptoms; stable or improving on established immunotherapy; no active seizures; able to perform basic ADLs; reliable follow-up within 1-2 weeks; no significant autonomic instability; family/caregiver education completed; outpatient infusion arranged if needed</td>
</tr>
<tr>
<td><strong>Admit to floor (medical/neurology)</strong></td>
<td>New-onset encephalitis requiring workup and immunotherapy initiation; seizures requiring medication adjustment; moderate behavioral symptoms manageable on floor; needs IV steroids/IVIG; diagnostic uncertainty requiring expedited workup</td>
</tr>
<tr>
<td><strong>Admit to ICU</strong></td>
<td>Refractory status epilepticus; altered consciousness (GCS &lt;12); severe autonomic instability (hemodynamic swings, arrhythmias, central hypoventilation); need for continuous EEG monitoring; requirement for mechanical ventilation; severe catatonia unresponsive to lorazepam; frequent or prolonged seizures requiring IV anesthetic infusions</td>
</tr>
<tr>
<td><strong>Transfer to higher level of care</strong></td>
<td>PLEX or continuous EEG not available; neurology/neuroimmunology specialist not available; need for tumor resection (gynecologic oncology for teratoma); requires ICU care not available at current facility</td>
</tr>
<tr>
<td><strong>Inpatient rehabilitation</strong></td>
<td>Medically stable; significant functional deficits requiring intensive therapy (cognitive, motor, speech); unable to safely return home; expected to benefit from structured rehabilitation program</td>
</tr>
<tr>
<td><strong>Long-term acute care (LTAC)</strong></td>
<td>Prolonged ventilator dependence (common in severe anti-NMDAR); medically complex care needs; ongoing immunotherapy requirements; unable to participate in intensive rehab</td>
</tr>
<tr>
<td><strong>Skilled nursing facility</strong></td>
<td>Stable but unable to perform ADLs independently; requires ongoing nursing care; awaiting rehabilitation bed; chronic disability</td>
</tr>
<tr>
<td><strong>Outpatient follow-up</strong></td>
<td>All discharged patients: neurology follow-up within 1-2 weeks; infusion center for ongoing immunotherapy; neuropsychology referral; rehab services; tumor surveillance per protocol</td>
</tr>
<tr>
<td><strong>Readmission criteria</strong></td>
<td>New seizures after period of control; behavioral/cognitive regression; fever or signs of infection on immunotherapy; suspected relapse (any new neurologic/psychiatric symptoms)</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="8-evidence-references">8. EVIDENCE &amp; REFERENCES<a class="headerlink" href="#8-evidence-references" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Evidence Level</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graus 2016 diagnostic criteria for autoimmune encephalitis</td>
<td>Expert Consensus, Class III</td>
<td>Graus F et al. Lancet Neurol 2016;15:391-404</td>
</tr>
<tr>
<td>CSF antibody testing more sensitive than serum for anti-NMDAR</td>
<td>Class II</td>
<td>Dalmau J et al. Lancet Neurol 2008;7:1091-1098</td>
</tr>
<tr>
<td>Cell-based assay (CBA) is gold standard for antibody detection</td>
<td>Class II</td>
<td>Waters P et al. J Neurol Neurosurg Psychiatry 2014</td>
</tr>
<tr>
<td>First-line immunotherapy: IV steroids + IVIG or PLEX</td>
<td>Class III, Expert Consensus</td>
<td>Titulaer MJ et al. Lancet Neurol 2013;12:157-165</td>
</tr>
<tr>
<td>Early immunotherapy improves outcomes</td>
<td>Class II</td>
<td>Titulaer MJ et al. Lancet Neurol 2013;12:157-165</td>
</tr>
<tr>
<td>Rituximab as second-line therapy</td>
<td>Class III, Retrospective</td>
<td>Lee WJ et al. JAMA Neurol 2016;73:197-205</td>
</tr>
<tr>
<td>Early second-line (rituximab) improves anti-NMDAR outcomes</td>
<td>Class III</td>
<td>Titulaer MJ et al. Lancet Neurol 2013;12:157-165</td>
</tr>
<tr>
<td>Cyclophosphamide as second-line therapy</td>
<td>Class III, Expert Consensus</td>
<td>Dalmau J &amp; Graus F. N Engl J Med 2018;378:840-851</td>
</tr>
<tr>
<td>Tocilizumab for refractory autoimmune encephalitis</td>
<td>Class IV, Case Series</td>
<td>Lee WJ et al. JAMA Neurol 2018</td>
</tr>
<tr>
<td>Bortezomib for refractory autoimmune encephalitis</td>
<td>Class IV, Case Series</td>
<td>Scheibe F et al. J Neurol 2017</td>
</tr>
<tr>
<td>Ovarian teratoma resection is essential in anti-NMDAR</td>
<td>Class II</td>
<td>Titulaer MJ et al. Lancet Neurol 2013</td>
</tr>
<tr>
<td>Tumor screening by antibody type</td>
<td>Expert Consensus</td>
<td>Graus F et al. Lancet Neurol 2016</td>
</tr>
<tr>
<td>Extreme delta brush on EEG in anti-NMDAR</td>
<td>Class III</td>
<td>Schmitt SE et al. Epilepsia 2012</td>
</tr>
<tr>
<td>Faciobrachial dystonic seizures precede LGI1 encephalitis</td>
<td>Class III</td>
<td>Irani SR et al. Brain 2011;134:2802-2818</td>
</tr>
<tr>
<td>Hyponatremia in LGI1 encephalitis (SIADH mechanism)</td>
<td>Class III</td>
<td>Lai M et al. Ann Neurol 2010;67:428-440</td>
</tr>
<tr>
<td>GABA-B encephalitis and SCLC association (~50%)</td>
<td>Class III</td>
<td>Lancaster E et al. Ann Neurol 2010;67:594-601</td>
</tr>
<tr>
<td>Anti-NMDAR encephalitis staging and recovery pattern</td>
<td>Class II</td>
<td>Dalmau J et al. Lancet Neurol 2019</td>
</tr>
<tr>
<td>Modified Rankin Scale for outcome tracking</td>
<td>Validated Scale</td>
<td>van Swieten JC et al. Stroke 1988</td>
</tr>
<tr>
<td>CASE score for autoimmune encephalitis assessment</td>
<td>Validated Scale</td>
<td>Lim JA et al. Neurology 2019</td>
</tr>
<tr>
<td>Catatonia in anti-NMDAR encephalitis (~40%)</td>
<td>Class III</td>
<td>Al-Diwani A et al. Lancet Psychiatry 2019</td>
</tr>
<tr>
<td>Lorazepam challenge for catatonia</td>
<td>Expert Consensus</td>
<td>Bush G et al. Acta Psychiatr Scand 1996</td>
</tr>
<tr>
<td>NMS risk with antipsychotics in anti-NMDAR</td>
<td>Class IV, Case Reports</td>
<td>Lejuste F et al. J Neurol Neurosurg Psychiatry 2016</td>
</tr>
<tr>
<td>Levetiracetam as preferred ASM in autoimmune encephalitis</td>
<td>Expert Consensus</td>
<td>Britton J. Epilepsy Curr 2016</td>
</tr>
<tr>
<td>Avoid carbamazepine in LGI1 (worsens hyponatremia)</td>
<td>Expert Consensus</td>
<td>Irani SR et al. Brain 2010</td>
</tr>
<tr>
<td>Long-term rituximab maintenance prevents relapse</td>
<td>Class III</td>
<td>Nosadini M et al. JAMA Neurol 2015</td>
</tr>
<tr>
<td>Anti-NMDAR relapse rate 12-20%</td>
<td>Class II</td>
<td>Titulaer MJ et al. Lancet Neurol 2013</td>
</tr>
<tr>
<td>Mycophenolate as steroid-sparing agent</td>
<td>Class IV</td>
<td>Expert practice; no large trials</td>
</tr>
<tr>
<td>Autonomic instability management in anti-NMDAR</td>
<td>Expert Consensus</td>
<td>Dalmau J &amp; Graus F. N Engl J Med 2018</td>
</tr>
<tr>
<td>Repeat tumor screening q6 months x 2-4 years</td>
<td>Expert Consensus</td>
<td>Graus F et al. Lancet Neurol 2016</td>
</tr>
<tr>
<td>Central hypoventilation in severe anti-NMDAR requiring prolonged ventilation</td>
<td>Class III</td>
<td>Florance NR et al. Ann Neurol 2009</td>
</tr>
<tr>
<td>Neuropsychological recovery trajectory in autoimmune encephalitis</td>
<td>Class III</td>
<td>Finke C et al. JAMA Neurol 2017</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="clinical-decision-support-notes">CLINICAL DECISION SUPPORT NOTES<a class="headerlink" href="#clinical-decision-support-notes" title="Permanent link">&para;</a></h2>
<h3 id="graus-2016-diagnostic-criteria-possible-autoimmune-encephalitis">Graus 2016 Diagnostic Criteria -- Possible Autoimmune Encephalitis<a class="headerlink" href="#graus-2016-diagnostic-criteria-possible-autoimmune-encephalitis" title="Permanent link">&para;</a></h3>
<p>All three of the following must be met:
- [ ] Subacute onset (rapid progression of &lt;3 months) of working memory deficits, altered mental status, or psychiatric symptoms
- [ ] At least one of: (a) new focal CNS findings, (b) seizures not explained by prior seizure disorder, (c) CSF pleocytosis (WBC &gt;5), (d) MRI features suggestive of encephalitis
- [ ] Reasonable exclusion of alternative causes</p>
<h3 id="anti-nmdar-encephalitis-clinical-staging">Anti-NMDAR Encephalitis Clinical Staging<a class="headerlink" href="#anti-nmdar-encephalitis-clinical-staging" title="Permanent link">&para;</a></h3>
<ol>
<li><strong>Prodromal phase</strong> (days to 2 weeks): Fever, headache, URI-like symptoms</li>
<li><strong>Psychiatric phase</strong> (weeks 1-2): Psychosis, paranoia, agitation, bizarre behavior, hallucinations, anxiety, insomnia</li>
<li><strong>Unresponsive phase</strong> (weeks 2-4): Decreased consciousness, catatonia, mutism</li>
<li><strong>Hyperkinetic phase</strong> (weeks 2-8): Orofacial dyskinesias, choreoathetosis, dystonic posturing, autonomic instability</li>
<li><strong>Recovery phase</strong> (months to years): Gradual improvement in reverse order of symptom onset; prolonged cognitive/behavioral deficits</li>
</ol>
<h3 id="red-flags-for-autoimmune-encephalitis">Red Flags for Autoimmune Encephalitis<a class="headerlink" href="#red-flags-for-autoimmune-encephalitis" title="Permanent link">&para;</a></h3>
<ul class="task-list">
<li class="task-list-item"><label class="task-list-control"><input type="checkbox" disabled/><span class="task-list-indicator"></span></label> Young female with new-onset psychiatric symptoms + seizures (consider anti-NMDAR)</li>
<li class="task-list-item"><label class="task-list-control"><input type="checkbox" disabled/><span class="task-list-indicator"></span></label> Limbic encephalitis + hyponatremia (consider LGI1)</li>
<li class="task-list-item"><label class="task-list-control"><input type="checkbox" disabled/><span class="task-list-indicator"></span></label> Faciobrachial dystonic seizures (pathognomonic for LGI1)</li>
<li class="task-list-item"><label class="task-list-control"><input type="checkbox" disabled/><span class="task-list-indicator"></span></label> Refractory status epilepticus in young patient (consider GABA-A, GABA-B, NMDAR)</li>
<li class="task-list-item"><label class="task-list-control"><input type="checkbox" disabled/><span class="task-list-indicator"></span></label> Psychiatric presentation with CSF pleocytosis (encephalitis, NOT primary psychiatric)</li>
<li class="task-list-item"><label class="task-list-control"><input type="checkbox" disabled/><span class="task-list-indicator"></span></label> Encephalopathy + ovarian teratoma (consider anti-NMDAR)</li>
<li class="task-list-item"><label class="task-list-control"><input type="checkbox" disabled/><span class="task-list-indicator"></span></label> Extreme delta brush on EEG (pathognomonic for anti-NMDAR)</li>
<li class="task-list-item"><label class="task-list-control"><input type="checkbox" disabled/><span class="task-list-indicator"></span></label> Encephalopathy + movement disorder (orofacial dyskinesias) + autonomic instability</li>
<li class="task-list-item"><label class="task-list-control"><input type="checkbox" disabled/><span class="task-list-indicator"></span></label> New-onset refractory status epilepticus (NORSE/FIRES) -- screen for autoimmune etiology</li>
<li class="task-list-item"><label class="task-list-control"><input type="checkbox" disabled/><span class="task-list-indicator"></span></label> Rapidly progressive encephalopathy with seizures in a smoker (consider GABA-B + SCLC)</li>
</ul>
<hr />
<h2 id="change-log">CHANGE LOG<a class="headerlink" href="#change-log" title="Permanent link">&para;</a></h2>
<p><strong>v1.0 (January 27, 2026)</strong>
- Initial creation
- Section 1: 24 core labs (1A), 20 antibody panel tests (1B), 16 rare/specialized tests (1C)
- Section 2: 6 essential imaging/studies (2A), 7 extended (2B), 5 rare (2C), 22 LP/CSF studies
- Section 3: Expanded to 7 subsections:
  - 3A: 5 acute/emergent treatments (empiric acyclovir, antibiotics, benzodiazepines, catatonia challenge)
  - 3B: 5 first-line immunotherapy agents (methylprednisolone, omeprazole, insulin, IVIG, PLEX)
  - 3C: 6 second-line immunotherapy agents (rituximab, cyclophosphamide, tocilizumab, bortezomib, repeated IVIG/PLEX, oral prednisone taper)
  - 3D: 10 anti-seizure medications including refractory/super-refractory status epilepticus protocols
  - 3E: 9 psychiatric symptom management agents (antipsychotics, lorazepam for catatonia, ICU sedation, mood stabilization, ECT)
  - 3F: 12 ICU-specific treatments (ventilation, autonomic instability, DVT prophylaxis, temperature management, sodium correction)
  - 3G: 6 long-term immunosuppression/maintenance agents (mycophenolate, azathioprine, rituximab maintenance, prednisone, IVIG maintenance, bone protection)
- Section 4: 17 referrals (4A), 15 patient/family instructions (4B), 11 tumor screening protocols by antibody type (4C)
- Section 5: 16 differential diagnoses with distinguishing features
- Section 6: 16 acute monitoring parameters (6A), 15 outpatient/long-term monitoring parameters (6B)
- Section 7: 9 disposition criteria
- Section 8: 30 evidence references with evidence levels
- Clinical Decision Support Notes: Graus 2016 diagnostic criteria checklist, anti-NMDAR clinical staging (5 phases), 10 red flags checklist</p>












                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
        
<div class="md-social">
  
    
    
    
    
      
      
    
    <a href="https://github.com/blondarb/neuro-plans" target="_blank" rel="noopener" title="github.com" class="md-social__link">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    
      
      
      <script id="__config" type="application/json">{"annotate": null, "base": "../..", "features": ["navigation.instant", "navigation.tracking", "navigation.sections", "navigation.expand", "navigation.top", "search.suggest", "search.highlight", "content.code.copy"], "search": "../../assets/javascripts/workers/search.2c215733.min.js", "tags": null, "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}, "version": null}</script>
    
    
      <script src="../../assets/javascripts/bundle.79ae519e.min.js"></script>
      
        <script src="../../assets/js/comments.js"></script>
      
    
  </body>
</html>